Aldose reductase, a member of the aldo-keto reductase family, has been implicated in the development of vascular and neurological complications in diabetes. Despite recent studies from our laboratory demonstrating protection of ischemic hearts by an aldose reductase inhibitor, the presence and influence of aldose reductase in cardiac tissue remain unknown. Our goal in this study was to isolate and characterize the kinetic properties of cardiac aldose reductase, as well as to study the impact of flux via this enzyme on glucose metabolism and contractile function in hearts subjected to ischemia-reperfusion. Results demonstrate that ischemia increases myocardial aldose reductase activity and that these increases are, in part, due to activation by nitric oxide. The kinetic parameter of cardiac aldose reductase (K cat ) was significantly higher in ischemic tissues. Aldose reductase inhibition increased glycolysis and glucose oxidation. Aldose reductase inhibited hearts, when subjected to ischemia/reperfusion, exhibited less ischemic injury and was associated with lower lactate/pyruvate ratios (a measure of cytosolic NADH/NAD + ), greater tissue content of adenosine triphosphate, and improved cardiac function. These findings indicate that aldose reductase is a component of ischemic injury and that pharmacological inhibitors of aldose reductase present a novel adjunctive approach for protecting ischemic hearts.
In recent years, studies have demonstrated the beneficial role of aldose reductase inhibitors in ischemia-reperfusion injury and vascular remodeling (16) (17) (18) (19) . Recently, we demonstrated that inhibition of aldose reductase protects hearts from ischemic injury and improves functional recovery on reperfusion (16, 17) . However, in the absence of diabetes, the influence of ischemia on cardiac aldose reductase activity, as well as the impact of flux via aldose reductase on myocardial fatty acid and glucose metabolism is not well understood. In this study, we demonstrate the activation of cardiac aldose reductase by ischemia and the impact of flux via aldose reductase on fatty acid and glucose oxidation.
MATERIALS AND METHODS
We performed all studies with the approval of the institutional animal care and use committee at Columbia University, New York. This investigation conforms with the Guide for the Care and Use of Laboratory Animals, published by the U.S. National Institutes of Health (NIH publication No. 1996) .
Isolated perfused heart preparation
Experiments were performed using an isovolumic isolated heart preparation as published earlier (20) (21) (22) . Male Wistar rats (300-350 g, 3-4 months old) were anesthetized with a mixture of ketamine (80 mg/kg) and xylazine (10 mg/kg). After deep anesthesia was achieved, hearts were excised rapidly, placed into iced saline, and perfused retrogradely at 37ûC in a nonrecirculating mode through the aorta at a rate of 12.5 ml/min. Hearts were perfused with modified KrebsHenseleit buffer containing (in mM) NaCl 118, KCl 4.7, CaCl 2 2.5, MgCl 2 1.2, NaHCO 3 25, glucose 5, palmitate 0.4, bovine serum albumin (BSA) 0.4, and 70 mU/L insulin. The perfusate was equilibrated with a mixture of 95% O 2 and 5% CO 2 , which maintained perfusate Po 2 > 600 mmHg. Left ventricular developed pressure (LVDP) and left ventricular end diastolic pressure (LVEDP) were measured using a latex balloon in the left ventricle. LVDP, heart rate, and coronary perfusion pressure were monitored continuously on a four-channel Gould recorder.
Ischemic heart tissue for aldose reductase characterization
Freeze-clamped hearts were used for measuring aldose reductase activity, immunoblotting, and immunohistochemical studies. Hearts were freeze-clamped after either baseline perfusion or lowflow (flow reduced from 12.5 ml/min to 0.7 ml/min) ischemia for 50 min. In the experiments involving the role of nitric oxide in influencing aldose reductase activity, hearts were perfused with nitric oxide synthase inhibitor and 1 mM N4-nitro-L-arginine methyl ester (L-NAME) and were subjected to 20 min of global ischemia. In the experiments involving nitric oxide donor, homogenates from normoxic hearts were treated with 50 µM s-nitroso-N-acetylpencillamine (SNAP) for 60 min, and the aldose reductase activity was measured in these homogenates.
Ischemia/reperfusion protocol
Hemodynamic function was monitored throughout the protocol. All hearts were paced at 300 beats/min with the use of pacing electrodes. Two groups of hearts were subjected to 50 min of low-flow ischemia (flow reduced from 12.5 ml/min to 0.7 ml/min) and 60 min of reperfusion. Perfusate temperature was maintained at 37ûC at all times during the protocol (i.e., during baseline, ischemia, and reperfusion). After an equilibration period of 30 min, the control group (CON, n=9) of hearts was perfused with modified Krebs-Henseleit buffer throughout ischemia and reperfusion.
In the second group of hearts, after the equilibration period of 30 min, hearts (n=6) were perfused with modified Krebs-Henseleit buffer containing 1 µM aldose reductase inhibitor zopolrestat (unbound), starting 10 min before ischemia and continuing throughout ischemia and reperfusion.
Enzyme assay
To determine aldose reductase activity, we homogenized hearts from each group with 5 mM phosphate buffered saline (PBS) containing 10 mM mercaptoethanol. The homogenates, obtained after centrifugation at 8,000 g for 30 min, are used for enzyme assay. Before the assay, protein concentration was determined by the method of Bradford (23) by using BSA as standard. The reductase activity was spectrophotometrically assayed by following the decrease of NADPH at 25 û C for 4 min as published in the literature (24). Briefly, the reaction mixture (total volume 1 ml) contained 0.1 mM NADPH, 100 mM substrate (DL-glyceraldehyde or L-xylose or Dglucuronate) and aldose reductase (approximately 100 mU) in 0.1 M phosphate buffer, pH 6.2. The reaction was started by adding the substrate (glyceraldehyde or xylose) as well as the same reaction mixture in which the substrate replaced by deionized water was used as a control. One enzyme unit (U) was defined as the activity consuming 1 µmole of NADPH per min at 25 û C. Kinetic calculations were conducted by using the public procedure "Binkin2" on the NIH Prophet computer system.
Enzyme preparation
Aldose reductase used for kinetic study was purified from both control and ischemic rat hearts by the series of chromatographic procedures as previously described (24). Briefly, we homogenized one rat heart with 2 ml of 20 mM imidazole buffer, pH 7.5, containing 7 mM 2-mercaptoethanol by using glass homogenizer. After the centrifugation at 10,000 x g for 10 min, the supernatant was applied to a column (2.5 × 60 cm) of Sephacryl G-100 (Pharmacia Fine Chemicals, Piscataway, NJ) and eluted with the same imidazole buffer. The fractions containing the activity were applied to a column (1.5 × 10 cm) of Matrex Gel Orange A (Amicon Corporation, Danvers, MA). After washing with the same imidazole buffer, aldose reductase was eluted with 20 mM imidazole buffer containing 0.1 mM NADPH. This enzyme fraction was purified further with chromatofocusing on Mono P (Pharmacia). After the enzyme fractions from the Orange A column was applied to a Mono P column equilibrated with 20 mM imidazole buffer, pH 7.5, containing 7 mM 2-mercaptoethanol, the column was developed at the flow rate of 1 ml/min with polybuffer 74 (Pharmacia) diluted 10 times by 7 mM 2-mercaptoethanol. Protein concentration of the fluent was monitored at 280 nm, and the peak of aldose reductase was collected.
Western blot and immunohistochemical studies
Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed by using a 12% acrylamide gel with NOVEX XCell II electrophoresis apparatus (NOVEX, San Diego, CA). Proteins were stained with Coomassie blue (Bio-Rad Laboratories, Hercules, CA). Protein loading per lane ranged from 40 mg to 80 mg per lane. For immunoblot, after the electrophoresis, the proteins were transferred onto the nitrocellulose membrane Protran For immunostaining, tissues were fixed in 10% formalin and embedded in paraffin. Sections were stained with goat anti-ratAR serum (1:100) for 1 h at 37ûC. The sites of primary antibody were detected by using rabbit antigoat peroxidase conjugated IgG for 30 min at 37ûC (1:200; Sigma). The immunostaining of aldose reductase was visualized with 3-amino-9 ethyl carbazole (Sigma) substrate for 5 min at room temperature. Controls were performed by using the same concentration of nonimmune goat serum.
Measurement of glycolysis, glucose, and palmitate oxidation
To determine the effect of aldose reductase inhibition on myocardial glucose and palmitate metabolism, hearts were perfused either with [U- 14 
Biochemical assay for lactate and pyruvate
Lactate and pyruvate were extracted from the freeze-clamped tissue by using perchloric acid and measured by using standard biochemical assays published in the literature (30, 31), whereas sorbitol in the extracts was measured by using a modified enzymatic assay of Malone et al (32) by us (16, 17, 29) .
Statistical methods
Data were analyzed by using INSTAT (GraphPad, San Diego, CA) software operating on an IBM compatible personal computer. Differences between different groups were assessed by using ANOVA for repeated measures, with subsequent Student-Newman-Keuls multiple comparisons post-tests if the P value for ANOVA was significant. All data are expressed as mean ± SD.
RESULTS

Cardiac aldose reductase activity
Aldose reductase activity was measured in hearts that were freeze-clamped under baseline, global zero-flow ischemia, and low-flow ischemia (Fig. 1) . Change in NADPH absorption was monitored spectrophotometrically in the presence of DL-glyceraldehyde as substrate. In order to confirm that the reduction of glyceraldehyde was due to the presence of aldose reductase and not aldehyde reductase, the assay was performed with D-glucuronic acid or xylose as substrate. The lack of aldose reductase activity when glucuronic acid (a preferred substrate for aldehyde reductase) was used as a substrate clearly indicated the activity of aldose reductase in hearts (and not aldehyde reductase). Figure 1 shows that the aldose reductase activity is increased during low-flow ischemia. We also observed similar increases in aldose reductase activity in hearts subjected to global ischemia (data not shown). Inhibition of aldose reductase with zopolrestat reduced the activity in all hearts by more than 95%.
Kinetic properties of aldose reductase from ischemic hearts
Because the activity of aldose reductase was higher in ischemic hearts, we performed kinetic studies on aldose reductase isolated and (200-fold) purified from both control and ischemic rat heart extracts ( Table 1) to examine for any potential differences in catalytic activity or turnover rate. The total amount of aldose reductase, by using the ELISA method, was not significantly different in control and ischemic hearts (data not shown). The kinetic parameter of cardiac aldose reductase (Kcat) and Vmax values were significantly higher in aldose reductase from ischemic hearts, whereas Km values were not different in both groups. Although the turnover rate (Kcat/Km) tends to be higher for aldose reductase from ischemic hearts, we found no statistically significant difference between the enzyme isolated from control and ischemic hearts.
Western blot and immunohistochemical characterization
The presence of aldose reductase in rat heart was confirmed further by Western blots of rat heart crude extracts (Fig. 2) . Both control and ischemic hearts displayed clearly the immunostaining that corresponded exactly to the purified rat lens aldose reductase. However, no obvious difference in the intensity of staining between the control and ischemic rats was observed. Similarly, data from Northern blot experiments demonstrated that aldose reductase mRNA expression was unchanged in control and ischemic hearts (data not shown). Immunohistologic analysis of aldose reductase (a representative slide shown in Fig. 3 ) demonstrates the presence of aldose reductase antigen in myocytes. Image analysis of sections similar to those shown in Figure 3 revealed similar image intensity of aldose reductase antigen in both control and ischemic hearts. These data suggest that increased aldose reductase activity ( Fig. 1 ) in ischemic heart is not due to increased expression, but rather due to activation of the enzyme by endogenous factors.
Influence of nitric oxide on myocardial aldose reductase activity
Recent studies have demonstrated that nitric oxide increases aldose reductase activity in cell culture (33) . Because ischemia increases myocardial nitric oxide (NO) levels (34-36), we examined whether this increase in NO could be a factor that may be responsible for activating aldose reductase. Increases in nitric oxide were confirmed by measuring changes in cGMP, a product formed when NO interacts with guanylase cyclase. cGMP increased from 183 ± 29 pmol/g dry wt under baseline conditions to 456 ± 45 pmol/g dry wt at the end of ischemia. Figure 4 shows that inhibition of NO by L-NAME, an inhibitor of nitric oxide synthase, lowered aldose reductase activity. Furthermore, incubation of homogenates from control hearts with an NO donor SNAP increased aldose reductase activity. Increases in aldose reductase activity with SNAP due to generation of NO is consistent with findings from recent in vitro studies showing activation of aldose reductase by SNAP-generated NO (7) . These data suggest that NO produced during ischemia is one mechanism by which aldose reductase activation occurs.
Aldose reductase activity was also measured in ischemic hearts perfused with dimethyl thiourea (DMTU), a known scavenger of oxygen-centered radicals such as superoxide and hydroxyl radicals. Absence of an effect of DMTU on aldose reductase activity in ischemic hearts suggests that oxygen-centered radicals may not be involved in increasing enzyme activity.
Aldose reductase inhibition on myocardial metabolism
The effect of aldose reductase inhibitor zopolrestat on glycolysis and glucose oxidation is demonstrated in Figure 5A , B. Rates of glycolysis and glucose oxidation were significantly higher in zopolrestat-perfused hearts under normoxic and ischemic conditions. Palmitate oxidation remained unaffected with aldose reductase inhibition ( 14 CO 2 release from 1-14C palmitate was 456 ± 102 µmoles/g dry wt. min in controls versus 411 ± 81 µmoles/g dry wt. min, n=6 in each group).
Consistent with increased glycolysis, ATP was significantly higher in aldose reductase-inhibited hearts during ischemia (Table 2) . Tissue lactate/pyruvate ratio, (a measure of cytosolic redox state NADH/NAD + ), was increased during ischemia (Table 2) , which was consistent with our earlier findings (16, 17) . Inhibition of aldose reductase with zopolrestat attenuated the increases in lactate/pyruvate ratio, suggesting that increases in cytosolic redox state are attenuated as well. Lactate in the effluent was significantly higher during ischemia in the aldose reductase inhibited hearts, a finding consistent with our earlier published study (17) , suggesting increased efflux of lactate from the heart. Pyruvate in the effluent was too low for detection by using the method used in this study.
One mechanism by which cytosolic redox state is likely to be attenuated by aldose reductase inhibition is by attenuating the flux of substrate through sorbitol dehydrogenase (which uses NAD + ). It is expected that increases in flux via sorbitol dehydrogenase may decrease flux via glyceraldehyde-3-phosphate dehydrogenase by competing for NAD + . Lactate/pyruvate ratio data suggest that aldose reductase inhibition likely conserves NAD + and aids glycolysis by reducing NAD + use by sorbitol dehydrogenase.
Effect of aldose reductase inhibition on cardiac function
LVDP and EDP were similar in all groups under baseline conditions (Table 3 ). During ischemia, the rise in EDP was greater in the control than in the aldose reductase inhibited hearts. On reperfusion, the aldose reductase inhibited hearts exhibited greater LVDP recovery than the untreated hearts. Myocardial oxygen consumption was similar in all groups under baseline, ischemic, and reperfusion conditions and was unaffected by aldose reductase inhibition (Table  3) .
Aldose reductase inhibition and protection of ischemic myocardium
The ability of aldose reductase inhibitor zopolrestat to reduce ischemic injury in the presence of fatty acids and insulin was determined in hearts perfused with physiological concentrations of palmitate and insulin. Creatine kinase release, a marker of ischemic injury, was significantly lower in aldose reductase inhibited hearts (Fig. 6) , the magnitude of reduction in ischemic injury similar to those obtained earlier (16) .
DISCUSSION
Aldose reductase is a member of the aldo-keto reductase family with a broad substrate specificity. Earlier studies from our laboratory demonstrated that pharmacological inhibition of aldose reductase protects perfused rat hearts from ischemic injury. Because aldose reductase inhibitors may also inhibit aldehyde reductase (EC 1.1.1.2), another member of aldo-keto reductase family (37, 38) , in addition to aldose reductase (EC 1.1.1.21) (39), we investigated whether myocardial levels of aldose reductase changed under normal and ischemic conditions. Furthermore, we isolated and characterized myocardial aldose reductase and determined its influence on substrate metabolism and ischemic injury. In the present study, we assayed the activity of aldose reductase with an aldose D-xylose as substrate in order to eliminate the NADPH-reducing activity arising from aldehyde reductase. Aldose reductase activity was higher in ischemic rat hearts compared with that of control hearts. Aldose reductase was detected clearly on Western blots, but with no appreciable differences in the intensity of the protein from normal and ischemic hearts. In Northern blots, the signal for aldose reductase was much more stronger than that for aldehyde reductase, again with differences between the two normal and ischemic groups. The absence of any differences in Western and Northern blots of aldose reductase from normal and ischemic hearts suggests that the increased activity observed during ischemia is not due to increased transcription or translation. However, these data clearly demonstrate the presence of aldose reductase in myocardial tissue under normal and ischemic conditions. Furthermore, the data also indicate that aldose reductase is the dominant aldo-keto reductase in the rat heart.
Aldose reductase has been known to exist in an activated form (oxidized form), with the conversion to activated form after purification demonstrated in bovine aldose reductase (40) and in human placental aldose reductase (41) . It is plausible that similar conformational changes of aldose reductase may occur in rat hearts during ischemia. It should be noted that our data were obtained on enzymes purified with the use of affinity chromatography and Orange A column. Because the activated (oxidized) enzyme does not bind to an Orange A column (42) , the kinetic data presented here may have underestimated the effects of enzyme conversion to the oxidized form in ischemic hearts.
Reactive oxygen species have been shown to influence aldose reductase activity (2-5, 43, 44) . A recent study by Nishimura et al (33) demonstrated that nitric oxide donors increase aldose reductase activity in cell culture. In this context, it is well known that ischemia increases myocardial nitric oxide levels (34) (35) (36) . Hence, we performed ischemia experiments in the presence of nitric oxide synthase inhibitor to determine whether increases in aldose reductase activity are associated with increased NO production during ischemia. The data showed that inhibition of nitric oxide synthase attenuated the increases in aldose reductase activity during ischemia. Furthermore, we also showed that incubation of cardiac homogenates with a nitric oxide donor increases aldose reductase activity. These data provide evidence that nitric oxide, in part, mediates activation of aldose reductase during ischemia.
The data demonstrating that ischemia increases myocardial aldose reductase activity and that pharmacological inhibition of aldose reductase is cardioprotective suggest that aldose reductase is a component of myocardial ischemic injury. In view of the complexities of cellular metabolic pathways, it is necessary to demonstrate that aldose reductase could impact substrate metabolism in response to ischemia. Moreover, pharmacological inhibition of aldose reductase increased myocardial glycolysis and glucose oxidation, as well as conserved ATP during ischemia. Furthermore, in this study we observed that aldose reductase inhibition in the presence of albumin-bound palmitate and insulin also reduced ischemic injury. This finding is consistent with the in vivo cardioprotection observed recently by Tracey et al (45) . The cascade of events that result in reducing ischemic injury as consequence of aldose reductase inhibition includes attenuation of increases in cytosolic redox state (1, 16, 17, 23, 29) , improved glycolytic metabolism and energy homeostasis (16, 17, 23, 29) , and attenuation of the rise in intracellular sodium and calcium during ischemia (46) . Furthermore, it has been postulated that aldose reductase inhibition can alter protein kinase C activity and influence intracellular sodium homeostasis and afford cardioprotection (1, 46) . In this context, we have shown that inhibition of protein kinase C protects ischemic myocardium by favorably influencing intracellular sodium homeostasis (47) . The current studies indicate that aldose reductase is a key component of ischemic injury and provide a foundation for evaluating aldose reductase inhibitors as potential therapeutic adjuncts in treating patients with myocardial infarction.
Limitations of this study
The data presented here were obtained from an isolated perfused heart model and hence should be interpreted within the limits of the experimental setting. Although we show activation of aldose reductase by nitric oxide, other factors such as increases in concentrations of other aldehyde substrates, NADPH, glucose-6-phosphate, and glycosylation, (2-5, 43, 44) as a mediator of increased aldose reductase activity, cannot be ruled out.
In conclusion, aldose reductase was isolated from normal and ischemic myocardial tissue and its kinetic properties were characterized. The enzyme activity was increased in ischemic hearts, with no apparent changes in any kinetic parameters. Treatment with inhibitor of nitric oxide synthase attenuated ischemia-induced increases in aldose reductase activity. Myocardial glycolysis and glucose oxidation were increased by inhibition of aldose reductase. Furthermore, inhibition of aldose reductase, in the presence of physiological concentrations of albumin-bound palmitate and insulin, reduced ischemic injury and improved energy homeostasis in ischemic hearts. These data indicate that aldose reductase is a component of myocardial response to ischemia and provide a foundation for evaluating aldose reductase inhibitors as potential therapeutic adjuncts in treating patients with myocardial infarction. 1 . Activity of cardiac aldose reductase in homogenates from various heart preparations. Homogenates were obtained from hearts subjected to normal perfusion (CON), low-flow ischemia (Ischemia), aldose reductase inhibitor treated controls (CON+ARI), and aldose reductase inhibitor treated subjected to ischemia (Ischemia+ARI). Six hearts per group were used in these experiments. Data are reported as mean Å standard deviation. *P < 0.02 CON versus CON+ARI and Ischemia+ARI, #P < 0.01 Ischemia versus CON+ARI & Ischemia+ARI, @ P < 0.02 Ischemia versus CON. inhibited using L-NAME in ischemic hearts. Nitric oxide donor SNAP was used to determine if aldose reductase could be activated using nitric oxide. *P < 0.04 versus other groups. Data are reported as mean ± SD. 
